

1 Beyond latent and active – a scoping review of conceptual 2 frameworks and diagnostic criteria for tuberculosis

3

4 Authors

5 Syed MA Zaidi^{1,2,3}, Anna K Coussens^{4,5,6}, James A Seddon^{7,8}, Tamara Kredon⁹, Digby Warner^{6,10},
6 Rein M G J Houben¹¹, Hanif Esmail^{1,2,6}

- 7 1. WHO Centre for Tuberculosis Research and Innovation, Institute for Global Health,
8 University College London, UK
- 9 2. MRC Clinical Trials Unit at University College London, UK
- 10 3. Department of Public Health, National University of Medical Sciences, Pakistan
- 11 4. Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of
12 Medical Research, Australia
- 13 5. Department of Medical Biology, University of Melbourne, Australia
- 14 6. Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and
15 Molecular Medicine, University of Cape Town, South Africa
- 16 7. Department of Infectious Disease, Imperial College London, UK
- 17 8. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch
18 University, South Africa
- 19 9. Health Systems Research Unit, South African Medical Research Council, Cape Town,
20 South Africa
- 21 10. Molecular Mycobacteriology Research Unit and Division of Medical Microbiology,
22 Department of Pathology, University of Cape Town, South Africa
- 23 11. TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, UK

24

25 Corresponding Author

26 Syed MA Zaidi
27 syed.zaidi.22@ucl.ac.uk

28

29

30

31

32

33

34

35

36

37

38 Abstract

39 Background

40 There is growing recognition that tuberculosis (TB) infection and disease exists as a spectrum of
41 states beyond the current binary classification of latent and active TB. Our aim was to
42 systematically map and synthesize published conceptual frameworks for different TB states
43 from the literature.

44 Methods

45 We searched MEDLINE, Embase and EMcare for systematic and narrative reviews without date
46 restrictions. We included articles that explicitly described greater than two states for TB. We
47 conducted a thematic and frequency analysis for terminologies, conceptual definitions and
48 diagnostic criteria for defined TB states.

49 Results

50 We identified 37 articles that met our inclusion criteria. All included articles were published after
51 2009. We identified eight broad conceptual themes that were used to categorize TB states and
52 to calculate their frequency among included articles. These states were: State 0: *Mycobacterium*
53 *tuberculosis* (*Mtb*) elimination by innate immune response (n=23/37, 62%); State I: *Mtb*
54 elimination by acquired immune response (n=28/37, 76%); State II: *Mtb* infection not eliminated
55 but controlled by immune system (n=34/37, 92%); State III: *Mtb* infection not controlled by the
56 immune system (n=21/37, 57%); State IV: bacteriologically positive without symptoms (n=23/37,
57 62%); State V: signs or symptoms associated with TB (n=36/37, 97%); State VI: severe or
58 disseminated TB disease (n=11/37, 30%); and State VII: previous history of TB (n=5/37, 14%).
59 We found 27 additional variations within these themes that were labelled as “sub-states.”
60 Articles varied in the terminology used to describe conceptual states and similar terms were

61 often used to describe different concepts. Diagnostic criteria were provided in 27 articles and
62 were also applied inconsistently.

63 Conclusion

64 Terminologies and definitions for TB states are highly inconsistent in the literature. Consensus
65 on a framework that includes additional TB states is required to standardize communication in
66 scientific publications as well as to inform advancements in research, clinical and public health
67 practice.

68

69

70

71

72

73

74

75

76 Panel: Research in context

77 Evidence before this study

78 The current paradigm of tuberculosis (TB) is based on a binary classification into “latent”
79 infection and “active” disease states. In recent years, there has been growing recognition that
80 this binary classification does not accurately reflect the complex pathophysiology of the disease
81 process and that it may also be inadequate for informing research and programmatic advances
82 for global TB elimination. While a number of articles have proposed multiple states of infection
83 and disease, no previous study has mapped and synthesized evidence from published literature
84 to inform an overarching and inclusive staging framework. We conducted a comprehensive
85 search on MEDLINE, Embase and EMCare databases for systematic or narrative review articles
86 or commentaries with terms related to TB and “states”, “stages,” “paradigm” “framework” or
87 “spectrum” without date restrictions. We included 37 articles that explicitly described TB as a
88 multi-state, i.e., beyond latent and active disease.

89 Added value of this study

90 To our knowledge, this is the first study to systematically review conceptual frameworks,
91 terminologies and diagnostic criteria for TB states beyond the latent and active paradigm. We
92 identified that there is substantial variation in the number of TB states described in the literature,
93 as well as in the concepts used to categorize them. Terms used for describing TB states and
94 their diagnostic criteria were also inconsistently applied.

95 Implications of all the available evidence

96 Our review highlights the need for a clear consensus on the overall conceptual framework,
97 terminology and diagnostic criteria for TB states. The inconsistency in TB states among articles
98 included in our review reflects diverse perspectives, academic interests and research priorities.
99 The consensus process should therefore aim to be inclusive so that a proposed framework can

100 be acceptable to a broad range of stakeholders including clinicians, researchers, public health
101 and policy practitioners, as well as to individuals living with or with experience of TB.

102 Introduction

103 An estimated 10.6 million individuals fell ill with tuberculosis (TB) in 2021 and the disease
104 caused 1.6 million deaths globally (1). TB elimination priorities, diagnostic approaches and
105 treatments for the past several decades have been based on a binary understanding of the
106 disease, described as having either latent infection or active (clinical) disease (2). While this
107 simplicity has facilitated the development of programmatic management of TB since it was
108 introduced over three decades ago, it has several limitations. Recent understanding of TB has
109 revealed a more complex pathophysiology with a spectrum of disease states, ranging from the
110 time of exposure to *Mycobacterium tuberculosis* (*Mtb*) bacilli to symptomatic, “active” disease
111 (3). Individuals within this spectrum likely differ in their prognostic and treatment outcomes,
112 however, their clinical management continues to be based on a binary understanding of the
113 disease (4). Individuals with early and unrecognized TB states may also be an important source
114 of community transmission and are therefore critical from an epidemiological perspective (5).
115 From a programmatic viewpoint, individuals with early disease can be potentially misdiagnosed
116 or missed by the health system. This is becoming increasingly relevant as active case-finding
117 interventions are being scaled-up across high-burden countries (6).

118
119 Numerous articles have been published recently motivating that TB should be considered as a
120 spectrum of disease states. However, authors often take different perspectives (e.g.
121 immunological, microbiological, public health) and it is currently unclear which states have been
122 commonly described in literature, what terms have been used to describe them, how should
123 they be defined, as well as what diagnostic tests can be used to identify them. There is a need
124 to map TB states beyond latent and active disease described in the literature to help guide
125 researchers, clinicians and policymakers. Therefore, the aim of this scoping review was to

126 collate the terminology, conceptual and diagnostic definitions utilized to describe the spectrum
127 of TB states beyond the latent and active paradigm.

128

129 **Methods**

130 The scoping review was conducted based on a protocol that was registered at the Open
131 Science Framework (OSF) (7). The review consisted of the following research questions: 1)
132 *what novel conceptual states have been described for TB beyond latent and active disease and*
133 *how can they be categorized; 2) what nomenclature has been used to describe novel TB states;*
134 *3) what are the diagnostic definitions for novel TB states; 4) which conceptual states of TB have*
135 *been described as potentially infectious and as representing TB disease; and 5) how have the*
136 *concepts and terms used for TB states have changed over time.* Due to the lack of working
137 definitions and absence of conceptual clarity on TB disease states, a scoping review
138 methodology was considered appropriate. The protocol was developed in accordance with the
139 recommendations provided by the Joanna Briggs Methods Manual for Scoping Reviews (8).
140 The scoping review objectives were developed with input from all authors. The inclusion criteria
141 and charting methods were developed by one author (SMAZ) and reviewed by another author
142 (HE) to improve the validity. The study protocol was developed by two authors (SMAZ and HE)
143 and reviewed by the remaining authors. The Preferred Reporting Items for Systematic reviews
144 and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) was utilized to guide the
145 reporting (9).

146 **Search Strategy and Data Sources**

147 To address research questions 1-4, we conducted a systematic search on MEDLINE, Embase
148 and EMcare databases on Ovid for terms related to TB states, stages or spectrum. The search
149 was conducted in December 2022 and no date restrictions were applied. The complete list of
150 terms utilized in the scoping review are described in Supplementary Table 1. A filter for “Review

151 Articles” was applied in Ovid. The search strategy was developed with input from a specialist
152 librarian at the UCL Great Ormond Street Institute of Child Health Library. In addition to the
153 database search for published review articles, to address research question 5, we separately
154 charted the history of classification of TB used by the National TB Association (NTA) of the
155 United States of America, from its foundation in 1904 to the current day. Transactions of the
156 annual meetings of the NTA and the published Diagnostic Standards (in there various formats)
157 from 1917 - 2016 were obtained (10). The findings from this historical review are summarized in
158 Box 1.

159 Inclusion Criteria

160 Eligible articles explicitly described TB as a multi-state disease, i.e. provided description of
161 states beyond the existing two-state latent and active disease paradigm. Included articles
162 consisted of reviews pertaining to a range of topics including TB pathogenesis,
163 symptomatology, immunology and bacteriology, diagnostics, vaccinology and transmission.
164 Only articles published in the English language were eligible for inclusion. Articles describing
165 specific diagnostic approaches or biomarkers without describing distinct conceptual states were
166 excluded. Articles limited to descriptions of TB pathology or bacteriology without describing TB
167 conceptual states within individuals were excluded. Articles with a focus on childhood or extra-
168 pulmonary TB only were excluded.

169 Screening, Data Abstraction and Charting

170 Outputs from the Ovid searches from the three databases were uploaded on Covidence and
171 duplicates were removed (11). Two authors (SMAZ and HE) independently reviewed abstracts
172 for inclusion. Conflicts were resolved through discussions based on the inclusion and exclusion
173 criteria. Full-text articles were assessed for eligibility by one author (SMAZ) and reviewed by a
174 second (HE). Conflicts on inclusion of articles after full-text reviews were resolved through
175 review by a third author (RMGJH).

176 The data-charting table was developed on MS Excel. Summary characteristics of the included
177 articles, textual descriptions of TB states, concepts and terminologies were abstracted.
178 Conceptual descriptions of TB states described as part of diagrams or within texts for each
179 article were tabulated. Due to the variation in frequency, descriptions and terminologies utilized
180 for disease states between articles, textual descriptions with common concepts were
181 thematically derived and coded. These conceptual themes were labelled as distinct “states” and
182 were subsequently categorized numerically. Extended descriptions or minor variations within
183 themes were separately coded in order to capture all described states. These were categorized
184 as “sub-states” and categorized alphanumerically. Frequency of each state and sub-state
185 among included articles were calculated. Two authors (SMAZ and HE) developed the coding
186 and all authors reviewed the development of the final descriptions of TB states. Data-abstraction
187 and coding was conducted by two authors (SMAZ and HE) and conflicts on the coding were
188 resolved by mutual discussion. Disagreements on coding for TB states were resolved by a third
189 author (RMGJH). One author (HE) reviewed proceedings from the NTA and abstracted
190 historical timelines for the usage of various terminologies for describing TB disease states
191 To record diagnostic criteria, outcomes of diagnostic tests and symptomatology described for
192 each state were extracted from the articles. These were categorized as positive,
193 positive/negative (i.e. test could be either positive or negative), negative, or not described.
194 Frequency statistics describing diagnostic tests and symptomatology as positive or
195 positive/negative for each state were calculated. Frequency of articles describing each state as
196 potentially infectious and as representing TB disease were also calculated.

197 Results

198 Literature search

199 A total of 2,138 articles were identified through the database search (Figure 1). A further seven
200 articles were identified through recommendations of the contributing authors. After removing

201 duplicates, 1,512 article abstracts were screened, from which 64 full-text articles were assessed
202 for eligibility. A total of 37 articles were included in the final qualitative synthesis. Most excluded
203 articles (89%, n=24/27) did not describe TB as a multi-state disease. Articles focused on a
204 singular aspect of the disease, such as pathology without describing states that would be of
205 clinical or epidemiological relevance, were also excluded (11%, n=3/27). Nearly all of the
206 included articles had conceptual diagrams with descriptions outlining disease states and their
207 transitions.

208 Characteristics of the included articles

209 Most articles consisted of narrative reviews (78%, n=29/37) (Table 1). Three articles (8%) were
210 perspectives, two were systematic reviews and one a mathematical model. Most articles were
211 primarily focused on novel understandings of TB pathogenesis (46%, n=17/37). The remaining
212 articles described novel diagnostic approaches for TB (27%, n=10/37), advances in vaccine
213 development (8%, n=3/37), epidemiological or transmission implications of early TB states
214 (16%, n=6/37) and radiological findings of early TB (3% n=1/37). Most articles (91%, n=34/37)
215 were written by primary authors based in high-income countries.

216 All the articles were published from 2009 onwards, with 13 (35%) being published during or after
217 2020. This reflects the relative novel conceptualization of TB as a multi-state disease within
218 contemporary literature. However, as described in Box 1, such conceptual states were
219 recognized and described in the pre-antibiotic era.

220 Conceptual definitions of TB states

221 A total of eight distinct conceptual themes were identified that were categorized as TB states
222 (Table 2). We categorized the first state as **State 0** and this was described in 23 (62%) articles.
223 The conceptual theme for this state was elimination of *Mtb* through innate immunity due to
224 absence of detectable acquired immune memory to *Mtb* infection. Uninfected individuals were

225 also categorized as State 0. The most common terms for this state were '*innate immune*
226 *response*', '*innate immune elimination*' and '*uninfected*.' **State I** described in 28 (76%) articles
227 was conceptually similar to State 0 in that the infection was eliminated. However, the elimination
228 was described as involving an acquired immune response. This host response was frequently
229 described as detectable and these individuals were categorized as distinct from those who were
230 uninfected. The most used terms for this state were "*acquired immune*," "*adaptive immune*
231 *response*" and "*latent tuberculosis infection (LTBI)*." Individuals in **State II** described in 34 (92%)
232 articles were categorized as those in whom *Mtb* has not been eliminated, however, the infection
233 was described to be controlled by the immune system. This state was most commonly
234 described as "*quiescent infection*", "*latent tuberculosis infection*" and "*incipient TB*". **State III**
235 described in 21 (57%) articles was categorized as individuals in whom there was a failure to
236 control the infection or a breakdown of immune control. The most commonly used terms for this
237 state were "*incipient*", "*incipient TB infection*", and "*incipient TB disease*." **State IV** described in
238 23 (62%) articles categorized individuals that were bacteriologically positive for TB but had no
239 symptoms, or had symptoms that were not recognized or were not seeking care for symptoms.
240 The state was most frequently described as "subclinical" or "subclinical disease". In **State V**,
241 individuals had TB symptoms and signs and were actively seeking care. This state was
242 described in 36 (97%) of articles. This state was described as "*active TB disease*", "*clinical TB*"
243 or as "*disease*." **State VI** described in 11 (30%) articles was differentiated from the previous
244 state through terms describing increased disease severity such as cavitary disease,
245 disseminated or extensive disease. The most frequently utilized term for this state was
246 "*Cavitary/Disseminated*". **State VII** grouped all individuals with a previous history of TB including
247 those previously diagnosed, treated, or cured. This state was least frequently described,
248 featuring in only 5 articles (14%). Articles varied in the use of conceptual themes to describe
249 the TB spectrum (Table 3).

250 Within the eight states, we identified an additional 27 unique sub-states (Supplementary Table
251 2). These were variations or minor differences within the conceptual themes that we had used to
252 categorize. For States 0-I, conceptual variations included an acquired immune response that
253 was detectable versus no longer detectable and elimination of infection through administration
254 of preventative treatment. Conceptual sub-states for States II-IV differed in diagnostic results
255 such as detection of granulomas on imaging. State V had the largest number of sub-states with
256 articles describing variations in detection on imaging, bacteriological positivity and care-seeking
257 behavior.

258 Diagnostic criteria of TB states

259 Diagnostic criteria for TB states were described on the basis of tuberculin skin testing (TST),
260 interferon-gamma release assay (IGRA), computerized tomography (CT), positron emission
261 tomography combined with computerized tomography (PET-CT), X-ray, sputum culture, smear
262 and Xpert and symptomatology. Articles varied in the use of diagnostic tests to differentiate
263 states. Due to the variation in the descriptions of diagnostic tests described, we coded these
264 into 5 “diagnostic domains”. These domains were: 1) Immune sensitization (including IGRA,
265 TST); 2) High-resolution imaging (CT and PET-CT); 3) Chest X-ray; 4) bacteriology (including all
266 sputum based investigations) and 5) symptomatology. The proportion of articles describing each
267 diagnostic domain as either positive or positive/negative are displayed in Figure 2. Diagnostic
268 definitions or symptomatology were described in 27 (67% of total) articles either part of
269 diagrams, tables or within texts. Diagnostics were frequently not described for all states and not
270 every diagnostic domain was included in articles. Articles where the outcome of a diagnostic
271 test or symptom screen was not explicitly stated were categorized as missing and not included
272 in the numerator. Articles where some diagnostic information was provided but had missing
273 information for a particular diagnostic for a state have been retained in the denominator.

274 **State 0** was described as negative on all diagnostic tests with the exception of 3 (n=3/27; 11%)
275 articles describing positive/negative results on immune sensitivity tests. Individuals in **State I**
276 were most frequently described as having a positive diagnostic result to immune sensitization
277 tests (n=15/27; 56%) and negative to all other tests. Limited diagnostic differentiation was
278 described for **State II** with articles most frequently describing positive immune sensitivity tests
279 (n=16/27; 59%), followed by positive CT/PET-CT (n=3/27; 11%). **State III** was most frequently
280 described to be positive on X-ray (n=8/27; 30%) and PET-CT/CT (n=7/27; 26%). **State IV** was
281 frequently described as having positive bacteriologically (n=19/27; 70%) with remaining articles
282 describing this state as subclinical only, without providing explicit diagnostic results. **State V**
283 was most commonly described as having positive symptoms (n=23/27; 85%) with the remaining
284 articles not explicitly stating whether this state would yield positive symptom screen results.
285 **State VI** was most frequently associated with positive bacteriology (n=7/27; 26%) and
286 symptoms (n=4/27; 15%). **State VII** was most frequently associated with positive immune
287 sensitivity (n=2/27; 7%).

288 Infectiousness and disease threshold

289 To assess the epidemiological significance of each disease state, articles were reviewed for the
290 terms “*infectious*” or “*transmissible*.” To understand at which state articles considered TB
291 disease to begin (disease threshold), the term “*disease*” was reviewed. These terms were
292 included in the terminology, narrative descriptions or as part of conceptual diagrams for disease
293 states. No article described States 0, I or II as infectious or as disease. States IV and V were
294 most frequently described as infectious (n=10/37; 27% and n=14/37; 38% respectively) and as
295 disease (n=11/37; 30% and n=20/37; 54% respectively).

296 Discussion

297 This is the first review to systematically map and synthesize evidence from published literature
298 for additional TB states beyond the prevailing latent and active paradigm. We identified 37

299 articles relevant to our inclusion criteria, a third of which were published within the past three
300 years, suggesting increasing interest and recognition of additional states for TB. There are
301 several key themes that emerged from our review.

302 There was significant variation in the frequency of TB states and in their conceptual definitions,
303 highlighting an overall lack of consensus within literature. Articles varied in their focus and
304 emphasis, for example, TB pathogenesis and bacteriology, immunology, clinical or
305 epidemiological relevance, diagnostic biomarkers and imaging were utilized as different
306 perspectives for the basis of TB states. These perspectives framed the conceptual approach
307 towards TB states and subsequent inclusion or exclusion of particular states. The choice of
308 which states to include may also have been driven by prevailing knowledge gaps and research
309 priorities at the time of the article publication. Earlier articles (2009 – 2015/16) were broadly
310 more focused on TB immunology and host mechanisms of sterilization of *Mtb* and have
311 therefore described states with innate and adaptive clearance. More recent articles tended to
312 shift focus towards epidemiological considerations including detection and transmission
313 implications of asymptomatic disease. As a result, states describing subclinical disease were
314 more common. While we aimed to develop a parsimonious set of states grouped around
315 common concepts, there were variations within these themes that we described as *sub-states*.
316 Certain articles chose to further elaborate upon sub-states and this again reflected the focus of
317 the article and the perspective of the authors.

318 The review also highlights a lack of consistency in the terminologies used to describe TB states.
319 We observed that not only were different terms utilized to describe the same concept within the
320 natural history of disease but similar terms were also utilized to describe different conceptual
321 states. As examples, bacteriologically positive disease in the absence of symptoms was
322 variously described as *subclinical*, *asymptomatic*, *incipient* and *bacteriologically positive*.
323 Similarly, *latent TB* was utilized to describe elimination of infection with an identifiable acquired

324 immune response, containment of infection, as well as breakdown of immune control. Such
325 variation in nomenclature naturally leads to confusion in communication and conduct of
326 scientific research and in public health policy. The understanding of a certain term in literature is
327 subjective to the perspective of the authors and interpretation of the readers and these may not
328 necessarily be the same.

329 Two-thirds of articles outlined diagnostic criteria. Similar to the conceptual states, articles varied
330 in the choice of diagnostic tests to differentiate between states. The lack of a standardized
331 diagnostic criteria to differentiate between TB states may lead to further challenges in describing
332 TB states. We chose to group diagnostic criteria within five domains and these may prove useful
333 in developing diagnostic definitions for proposed conceptual states of TB. Further
334 considerations include achieving consensus on defining the domains themselves. Bacteriology
335 may be defined through culture, molecular tests, smear, as well as type of sampling, such as
336 through sputum, aerosols or through use of induced and invasive methods. Similarly,
337 symptomatology can include those who are truly asymptomatic, those who test negative on a
338 symptom-screen test or those who are symptomatic but do not seek clinical care.

339 From a public health and individual perspective respectively, the point at which TB is considered
340 infectious to others or as causing disease (and hence harm to the individual) is important. It is
341 notable therefore that the majority of articles did not directly address this concept.
342 Infectiousness of TB states was described by less than half of articles. No articles considered
343 State 0, I or II to be infectious, with this proportion steadily increasing from State III (infection not
344 controlled by immune system) to State IV (bacteriologically positive in the absence of
345 symptoms) and State V (clinically apparent symptomatic TB). Surprisingly, no articles explicitly
346 describe where they believed the disease threshold to begin and this could only be inferred from
347 terminology used in the text and in diagrams. The number of articles using the term disease
348 again increased from State III through to State V.

349 While it is clear that there is an increasing recognition of the TB spectrum in recent literature,
350 the various states outlined by the included articles are not all new. As our historical review of the
351 NTA proceedings highlights, TB in the past has been considered as having several stages, with
352 staging systems reflecting the public health needs of the time. Several of these early disease
353 states that have been highlighted in the contemporary literature we reviewed were also
354 described in the pre-antibiotic era (Box 1). In the absence of effective treatments, it was
355 recognized that screening, early-identification and prompt isolation of individuals with TB in
356 sanatoria may help control the disease. Development of potent chemotherapy for TB, coupled
357 with increased commitments for primary healthcare, shifted the focus away from mass X-Ray
358 based case finding towards passive approaches towards case-finding and treatment (12). This
359 cemented the binary conceptualization of TB, as individuals were either considered to be
360 harboring “latent” infection or presenting to healthcare facilities with clinically apparent, “active”
361 disease. It is possible that the reemergence of early TB disease states in literature over the past
362 decade has coincided with increased investments for active case-finding for TB, such as
363 through community-wide screening and use of mobile X-rays. In addition, improved
364 understanding of TB pathophysiology as well as advances in development of biomarkers and
365 imaging may have stimulated further interest in earlier disease states.

366 Our review underscores the need to develop a clear consensus on conceptual definitions,
367 terminologies and diagnostic criteria for TB states. This consensus should involve a broad range
368 of stakeholders so that agreed definitions and terminologies will be acceptable from research,
369 clinical, public health and policy perspectives, in addition to being acceptable to individuals with
370 TB. Standardized diagnostic definitions that can be consistently applied across different settings
371 will require careful consideration and are an important area for further research.

372 TB has a complex pathophysiology and as we have shown it is possible to describe many
373 states, hence the emergence of the commonly used phrase of “spectrum”. The binary

374 representation of TB is clearly insufficient, however, incorporating any additional states must
375 have a purpose and relevance to public health or to people with TB and should also facilitate the
376 goal of global TB elimination. Parsimony and simplicity should remain key guiding principles for
377 the development of this framework with clear language, diagnostic definitions and disease
378 thresholds. This will be of critical importance in communication to researchers, care providers,
379 people with TB and to the general public. Any framework should be regularly reviewed and
380 adapted as our knowledge improves along with advances in diagnostics and treatment.

381 **Limitations**

382 Our search strategy was restricted to review articles in English and it is likely that additional TB
383 states or terminology may have been described in other types of articles and languages.
384 However, since the aim of the scoping review was to provide an overview rather than to
385 comprehensively document all described states, this restriction was considered appropriate.

386 As with other types of thematic analyses, the categorization and coding for TB states is to a
387 degree subjective to the authors' interpretation and views. This is particularly relevant for states
388 where conceptual diagrams were not provided and categorization had to be inferred from the
389 article text. Our goal was to categorize states around a minimum number of common concepts,
390 not all variations described in the articles could be adequately captured within one of these
391 categories. We attempted to resolve this by including sub-states where such distinctions and
392 variations were categorized. Biases in coding were minimized by coding through two reviewers
393 and resolution by a third reviewer in cases of disagreement. All study authors reviewed the final
394 set of states and their diverse expertise and backgrounds helped further minimize bias.

395 Articles varied in the diagnostic tests and criteria utilized to classify diseases states depending
396 on the nature of the article and background of the authors. This led to a number of articles with
397 missing information on diagnostics, symptomatology, disease description and transmission
398 potential for those disease states. To remove potential for biases, a diagnostic test or criteria

399 was not included in the positive and positive/negative category unless explicitly stated in the
400 article. The ratios of positivity on diagnostic criteria are therefore lower than would be expected
401 had each article described them and should therefore be interpreted with caution and not as
402 precise measurements of the authors' opinions.

403 Conclusion

404 Early states of TB beyond latent and active disease have been increasingly described in
405 literature over the past decade. However, the conceptual definitions and diagnostic criteria for
406 these states and the terminology used to describe them is highly inconsistent. Consensus on a
407 framework for describing early TB disease states is therefore required. This will help
408 standardize how early TB disease is reported in literature, inform clinical and public health
409 management as well as guide research for TB elimination.

410

411 Acknowledgements

412 We would to thank Heather Chesters, Deputy Librarian, UCL Great Ormond Street Institute of
413 Child Health Library, UCL Library Services for support with the literature search.

414

415 Funding

416 This work was partially funded by a UKRI MRC grant (MR/V00476X/1) awarded to HE. HE is
417 partially supported through MRC unit grants (MC UU 00004/04). SMAZ is supported through the
418 Commonwealth Scholarship Commission (PKCS 2022-393). AKC is supported by NHMRC
419 (GNT2020750) and WEHI. RMGJH is supported by the European Research Council (Action
420 Number 757699)

421

422

423 **Tables**

424 **Table 1: Characteristics of the articles included in the scoping review**

Reference	Year	Title	Article Aims & Objectives	Type of Article
Barry 3rd et al.(3)	2009	The spectrum of latent tuberculosis: rethinking the biology and intervention strategies	Review of biology of latent TB, host responses and drug development	Review article
Young et al.(13)	2009	Eliminating latent tuberculosis	Review of heterogeneity in TB physiology and host immune response and impact on therapeutic and diagnostic approaches	Review article
Chao and Rubin(14)	2010	Letting sleeping dogs lie: does dormancy play a role in tuberculosis?	Description of in vitro models of TB dormancy and resuscitation during infection.	Review article
Achkar and Jenny-Avital(15)	2011	Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response	Review of early TB disease states and their impact on biomarker, diagnostics and drug discovery	Review article
Gideon and Flynn(16)	2011	Latent tuberculosis: what the host “sees”?	Review of human and non-human primate models of tuberculosis that have led to new concepts of latent tuberculosis	Review article
Kunnath-Velayudhan et al.(17)	2011	Immunodiagnosis of Tuberculosis: a Dynamic View of Biomarker Discovery	Review of clinical spectrum of M. tuberculosis infection, evolution of granulomatous lesions and granuloma structural changes	Review article
Lawn et al.(18)	2011	Changing Concepts of “Latent Tuberculosis Infection” in Patients Living with HIV Infection	Review of spectrum of TB bacteriology and immunology and implications for HIV associated TB	Review article
Sridhar et al.(19)	2011	Redefining latent tuberculosis	Review of latent TB biology, immunology and diagnostics	Review article
Esmail et al.(20)	2012	Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies	Review of current diagnosis and treatment of latent Mtb infection and developments in understanding the biology of latency	Review article
Joel D. Ernst(21)	2012	The immunological life cycle of tuberculosis	Descriptive framework for investigating immunity to M. tuberculosis to guide vaccine discovery and development.	Review article
Delogu et al.(22)	2013	The biology of mycobacterium tuberculosis infection	Review of advances in TB biology and pathogenesis and evolving paradigm of latent Mtb infection	Review article
Dowdy et al.(23)	2013	Is Passive Diagnosis Enough? The Impact of Subclinical Disease on	Estimate population-level impact of TB case-finding strategies in the presence of subclinical disease.	Mathematical Epidemic Model

		Diagnostic Strategies for Tuberculosis		
Delogu and Goletti(24)	2014	The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics	Review of TB disease spectrum	Review article
Esmail et al.(25)	2014	The ongoing challenge of latent tuberculosis	Review of current understanding of latent TB and highlight novel diagnostic, drug regimens and vaccines development approaches	Review article
Nunes-Alves et al.(26)	2014	In search of a new paradigm for protective immunity to TB	Review of advances in immune control of <i>M. tuberculosis</i> and implications for vaccine design and evaluation	Review article
Salgame et al.(27)	2015	Latent tuberculosis infection – Revisiting and revising concepts	Host, clinical and epidemiologic features of latent <i>Mtb</i> infection and diagnostic development	Review article
Pai and Behr(28)	2016	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays	Review of tests for latent TB diagnosis	Review article
Pai et al.(29)	2016	Tuberculosis	Review of the global TB epidemic	Review article
Petruccioli et al.(30)	2016	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis	Review of biomarkers for progression to active TB	Review article
Cadena et al.(31)	2017	Heterogeneity in tuberculosis	Review of TB biology and heterogeneity observed in the human disease	Review article
Drain et al.(32)	2018	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection	Review of current understanding of TB pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention	Review article
Kik et al.(33)	2018	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease	Descriptive framework for generating evidence to inform the development of policy guidance for tests for incipient TB	Review article
Lin et al.(34)	2018	The End of the Binary Era: Revisiting the Spectrum of Tuberculosis	Review of data supporting the spectrum of <i>M. tuberculosis</i> infection in humans and nonhuman primates	Review article
Sousaa and Saraiva(35)	2018	Paradigm changing evidence that alter tuberculosis perception and detection: Focus on latency	Review of new understandings of TB latency to inform research and elimination	Review article

Houben et al.(36)	2019	Spotting the old foe— revisiting the case definition for TB	Novel disease case definitions for TB	Perspective
Lewinsohn and Lewinsohn (37)	2019	New Concepts in Tuberculosis Host Defense	Review of TB immunology and novel host-directed therapies	Review article
McHenry et al.(38)	2020	Genetics and evolution of tuberculosis pathogenesis: New perspectives and approaches	Descriptive framework on possible transitions from pathogen exposure to TB disease and associated genetics studies	Review article
Boom et al.(39)	2021	The knowns and unknowns of latent <i>Mycobacterium tuberculosis</i> infection	Review of immune responses to Mtb in humans and nonhuman primates, new concepts and major knowledge gaps in understanding of latent Mtb infection	Review article
Kendall et al.(40)	2021	The Epidemiological Importance of Subclinical Tuberculosis A Critical Reappraisal	Conceptual framework for subclinical TB and transmission	Perspective
Migliori et al.(41)	2021	The definition of tuberculosis infection based on the spectrum of tuberculosis disease	Review of TB as a disease spectrum	Review article
Alebouyeh et al.(42)	2022	Feasibility of novel approaches to detect viable <i>Mycobacterium tuberculosis</i> within the spectrum of the tuberculosis disease	Review of feasibility of new approaches to detect TB bacilli across the full spectrum disease	Review article
Chandra et al.(43)	2022	Immune evasion and provocation by <i>Mycobacterium tuberculosis</i>	Review of TB biology, immunity and development of host-directed therapies, biomarkers and vaccines.	Review article
Esmail et al.(2)	2022	Mind the gap - Managing tuberculosis across the disease spectrum.	Review of tuberculosis as a spectrum of disease states, new diagnostic approaches and clinical trials	Review article
Houben et al.(5)	2022	Tuberculosis prevalence: beyond the tip of the iceberg	Novel stages and disease thresholds for TB	Perspective
Scriba et al.(44)	2022	Challenges in TB research	Challenges in developing new diagnostics and vaccines for TB control	Perspective
Yoon et al.(45)	2022	CT and 18F-FDG PET abnormalities in contacts with recent tuberculosis infections but negative chest X-ray	Systematic review of CT and PET-CT imaging of asymptomatic TB contacts with normal X-rays	Systematic review

Sossen et al.(4)	2023	The Natural History of Untreated Pulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis	Quantify progression and regression across the spectrum of TB disease of individuals with untreated TB during the pre-chemotherapy era	Systematic Review
------------------	------	--	--	-------------------

425

426

427 Table 2: TB states conceptual definitions and terminology

State	Conceptual Theme	Terminology Used to Describe State	Articles Describing State (n)	%
State 0	Infection has been eliminated by innate immune response	Uninfected, Innate immune Response, Innate immune elimination, No Disease (TB Negative), Eliminated TB infection, Infection controlled/ eliminated / Stable, Uninfected individual, No M. tuberculosis infection, Cleared, Latent Clearance, Uninfected, Initial infection, TB infection, Innate Immune Cell Recruitment, Colonization and Early Clearance, Infection, Resistance to Infection, Stage 1, Elimination of infection (self-resolving infection), Infection eliminated (with innate immune)	23	62%
State I	Infection has been eliminated by acquired immune response	Acquired Immune, Adaptive Immune Response, LTBI, No Disease (Latent TB), Acquired Immune Response, Acquired Immune Elimination – memory, LTBI – Asymptomatic, Eliminated TB infection, Acquired Immune, Infection controlled/ Eliminated / Stable, Non-progression or Self-cure from Subclinical Stage, Primary or secondary M. tuberculosis infection, LTBI – Reverter, Latent Clearance, Reduced Reactivation Risk, Adaptive Immune Phase, Transient Infection, Adaptive Immune Cell Activation, Resister, Clearance of Infection, Mtb infection, Latent TB infection, Asymptomatic - LTBI – Incident	28	76%
State II	Infection is not eliminated but is controlled by the immune system	Quiescent Infection, Latent Mtb infection, LTBI, Incipient TB, Latent Infection, No Disease (Latent TB), Quiescent, Unstable LTBI, Latent Non-infectious tuberculosis, Mtb infection, Immunological equilibrium (latency), Latent Subclinical or Low Grade TB, Primary Infection, Latent Infection - Dormant / Persistent, Traditional LTBI, Incipient TB, Caseating granuloma, Persistent TB, Containment of infection (Established Latency)	34	92%
State III	Infection is not controlled by the immune system	Incipient, Incipient TB infection, Incipient TB disease, No Disease (Latent TB), Active Infection, Subclinical - TB Disease, Asymptomatic, Incipient disease, Unstable LTBI Incipient, Infectious Tuberculosis, Active Severe TB, Resuscitation, Reactivation TB, Percolating Infection, Progressor / Incipient TB, Stage 2, Failure to Contain Infection (subclinical active TB), Culture-Negative TB	21	57%

State IV	Individual is bacteriologically positive but has no symptoms or clinical features	Subclinical, Subclinical TB Disease, Asymptomatic, Bacteriologically Positive, Subclinical Active Phase, Subclinical - No Symptoms, Additional Infectious Tuberculosis, Subclinical TB with no Signs/Symptoms, Subclinical Disease, Subclinical / Incipient, Active Infection, Incipient TB, Asymptomatic - Pre-clinical, Stage 3, Failure to contain infection (Primary Active TB), Subclinical Infection, Quiescent	23	62%
State V	Individual has signs or symptoms associated with TB	Active TB Disease, Clinical TB, Disease (Active TB), Disease, Minimal, Active TB Disease - Symptomatic Clinical Bacteriologically Negative, Pre-diagnostic TB Disease, Clinical TB, Subclinical - Symptoms not Recognized, Clinical Disease (Symptoms) - Infectious Period, Active Clinical TB Disease, Chronic TB, Reactivation / Secondary TB, Reactivation, TB Disease, Transmission, Active TB, Smear Negative, Active TB - Caseating Granuloma, At Risk for TB, Primary Active Disease, Active TB, Symptomatic – Clinical, Stage 4, Breakdown of Immune Control (Active TB), Definite TB	36	97%
State VI	High severity of disease due to clinical features, radiology or bacteriology	Cavitary/Disseminated, Active TB Disease - Symptomatic Clinical Smear Positive / Extensive Disease, Dissemination disease, Active, Severe, Symptomatic - Culture Positive - Smear Positive,	11	30%
State VII	Previous History of TB	Asymptomatic Past TB, No Disease (Past TB), Treated / Recovered, Treated, Old Disease, Relapse, Reinfection	5	14%

428

429 *Three most frequently used terms for each state are highlighted in bold. Abbreviated terms have*
 430 *been included as described in the article text, tables or diagrams. Tuberculosis (TB),*
 431 *Mycobacterium tuberculosis (Mtb), Latent Tuberculosis Infection (LTBI).*

432

433

434

435

436

437

438

439

440

441 Table 3: TB states described by articles included in the review

Reference	State 0	State I	State II	State III	State IV	State V	State VI	State VII
Barry 3rd et al. (2009)	X	X	X	X		X		
Young et al. (2009)	X	X	X	X		X		
Chao and Rubin (2010)		X	X	X		X		
Achkar and Jenny-Avital (2011)			X	X		X	X	X
Gideon and Flynn (2011)	X	X	X		X	X	X	
Kunnath-Velayudhan et al. (2011)			X		X	X	X	X
Lawn et al. (2011)	X	X	X		X	X		
Sridhar et al. (2011)	X	X	X	X		X		
Esmail et al. (2012)	X	X	X		X	X	X	
Joel D. Ernst (2012)	X		X	X			X	
Delogu et al. (2013)	X		X			X		
Dowdy et al. (2013)			X		X	X		X
Delogu and Goletti (2014)	X	X	X			X		
Esmail et al. (2014)		X	X	X	X	X		
Nunes-Alves et al. (2014)		X	X			X		
Salgame et al. (2015)	X	X	X	X	X	X	X	
Pai and Behr (2016)	X	X	X		X	X	X	

Pai et al. (2016)	X	X	X		X	X		
Petruccioli et al. (2016)	X	X	X	X	X	X		
Cadena et al. (2017)		X	X	X		X		
Drain et al. (2018)	X	X	X	X	X	X		
Kik et al. (2018)		X	X	X	X	X		
Lin et al. (2018)	X	X			X	X	X	
Sousaa and Saraiva (2018)	X	X	X	X		X		X
Houben et al. (2019)		X	X	X	X	X		
Lewinsohn and Lewinsohn (2019)	X	X	X		X	X		
McHenry et al. (2020)	X	X	X			X		
Boom et al. (2021)	X	X	X	X		X	X	
Kendall et al. (2021)	X	X	X	X	X	X		X
Migliori et al. (2021)	X	X	X		X	X		
Alebouyeh et al. (2022)		X		X	X	X		
Chandra et al. (2022)	X	X	X			X	X	
Esmail et al. (2022)			X	X	X	X	X	
Houben et al. (2022)				X	X	X		
Scriba et al. (2022)	X		X		X	X		

Yoon et al. (2022)		X	X	X	X	X		
Sossen et al. (2023)			X	X	X	X		


442

443

444 **Figures**

445 **Figure 1: Selection of sources of evidence**

446



469

470

471

472 Figure 2 Diagnostic criteria and description of TB states

State	Diagnostic Criteria (N = 27)											Description (N = 37)			
	No. of Articles	Immune Sensitization		High Resolution Imaging		X-ray		Bacteriology		Symptoms		Infectious		Disease	
		n	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n
State 0	27	3	11%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
State I	27	15	56%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
State II	27	16	59%	3	11%	2	7%	3	11%	0	0%	0	0%	0	0%
State III	27	6	22%	7	26%	8	30%	2	7%	2	7%	5	14%	6	16%
State IV	27	12	44%	6	22%	14	52%	19	70%	3	11%	10	27%	11	30%
State V	27	16	59%	7	26%	16	59%	20	74%	23	85%	14	38%	20	54%
State VI	27	4	15%	2	7%	4	15%	7	26%	4	15%	3	8%	4	11%
State VII	27	2	7%	0	0%	1	4%	0	0%	1	4%	2	5%	1	3%

473

474 *Number of articles (n) is total articles describing each TB state as positive or positive/negative
 475 on diagnostic tests, presence of symptomatology and whether the state was described as
 476 infectious or as disease. Total number of articles describing diagnostic criteria was 27 using
 477 which the proportions were calculated. Bacteriology includes positive or positive/negative on TB
 478 culture, smear or molecular tests. All articles were included in the denominator for proportions
 479 for infectious and disease.

480

481

482

483 Box 1: TB Disease states: historical perspective

484 The articles that form part of this scoping review are all recent which in part reflects the search
485 strategy, selection of databases and inclusion criteria. However, discussions and debates on the
486 classification of TB have been ongoing since well before Koch's discovery of *Mycobacterium*
487 *tuberculosis*. Historical literature and the Diagnostic Standards and Classification of
488 Tuberculosis of the (American) National Tuberculosis Association (published periodically since
489 1917) highlight an evolving classification of TB driven by changing priorities for TB control,
490 available diagnostics and treatments (10).

491 As early as the early nineteenth century, authors referred to and discussed the merits of staging
492 systems for TB with terminology such as *phthisis incipiens* (incipient TB), *phthisis confirmata*
493 (confirmed TB) and *phthisis desperata* (desperate/severe TB) in use (46, 47). By the early
494 twentieth century there were numerous staging systems reflecting different perspectives, for
495 instance based on pathology, diagnosis, extent, presentation or disease course (47-49). It was
496 recognized that there was a tension between complex classification systems capturing multiple
497 dimensions of the disease accurately vs. simplistic approaches such as the 3-stage Turban-
498 Gerhardt classification based on disease extent that was could be more easily applied and
499 hence widely implemented but proved unsatisfactory (48, 49).

500 While TB continued to be largely managed in sanatoria, microbiological, radiological and other
501 diagnostic tools to assess the state of disease were becoming increasingly available and the
502 need for a standardized approach to disease classification was recognized to aid statistical
503 comparisons and clinical communication. In particular, it was considered important to have a
504 consistent approach to classifying the condition of the patient at entry into the sanatoria
505 (reflecting prognosis) and the condition during follow-up and at discharge (reflecting the degree
506 of cure/healing and likelihood of relapse). Soon after inception of the National Tuberculosis
507 Association in 1904, a *Committee on Clinical Nomenclature* was formed (50, 51). Discussions,
508 surveys and consensus-building for over a decade led to the development of the 1st Diagnostic
509 Standards and Classification of Tuberculosis in 1917 (52). Here the classification of pulmonary
510 TB in adults consisted of 3 dimensions each clearly defined; (i) the extent of pulmonary lesions -
511 initially categorized as incipient, moderately advanced and far advanced (ii) symptoms -
512 categorized slight/none, moderate (iii) clinical/treatment status – initially suspicious case,
513 definite case, arrested/apparently arrested case. Over subsequent iterations details were
514 added, clinical status became more nuanced, bacteriology was increasingly emphasized and
515 there were changes to terminology. However, the broad classification approach remained
516 similar with a focus on stratification by disease extent and clinical status (51).

517 The availability of antibiotics from the 1950's for both curative and preventive therapy resulted in
518 a radical change in the approach to managing tuberculosis and eventually led to a shift in
519 disease classification (53). Prognostic considerations and clinical status became less relevant
520 as treatment remained the same for all individuals and prolonged follow-up for relapse was not
521 required. The 13th edition of the Diagnostic Standards in 1974 were a major departure from
522 previous classifications highlighting 5 states; *0: No tuberculosis exposure, not infected, I:*
523 *Tuberculosis exposure, not infected, II: Tuberculosis infection, without disease, III: Tuberculosis*
524 *infection, with disease, IV: Tuberculosis suspect* (53). Central to this classification was diagnosis
525 of infection requiring evidence of immune sensitization without evidence of disease (symptoms,
526 radiological or microbiological) and of disease through microbiological confirmation. Finally in

527 1999, the term *latent* was prefaced to *tuberculosis infection, no disease* to distinguish from
528 *clinically active tuberculosis*, leading to the binary paradigm in use to the present day (54).

529

530 References

- 531 1. Global tuberculosis report 2022. Global Tuberculosis Programme. World Health
532 Organization [Available from: [https://www.who.int/teams/global-tuberculosis-programme/tb-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports)
533 [reports](https://www.who.int/teams/global-tuberculosis-programme/tb-reports)].
- 534 2. Esmail H, Macpherson L, Coussens AK, Houben R. Mind the gap - Managing
535 tuberculosis across the disease spectrum. *EBioMedicine*. 2022;78:103928.
- 536 3. Barry CE, 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of
537 latent tuberculosis: rethinking the biology and intervention strategies. *Nat Rev Microbiol*.
538 2009;7(12):845-55.
- 539 4. Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al.
540 The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-
541 analysis. *Lancet Respir Med*. 2023;11(4):367-79.
- 542 5. Houben R, Esmail H, Cobelens F, Williams CML, Coussens AK. Tuberculosis
543 prevalence: beyond the tip of the iceberg. *Lancet Respir Med*. 2022;10(6):537-9.
- 544 6. Biermann O, Lonnroth K, Caws M, Viney K. Factors influencing active tuberculosis case-
545 finding policy development and implementation: a scoping review. *BMJ Open*.
546 2019;9(12):e031284.
- 547 7. Zaidi SMA, Esmail H. Conceptual and diagnostic definitions for tuberculosis (TB) stages:
548 a scoping review. *Open Science Framework* [Available from: <https://osf.io/qjf2w>].
- 549 8. Joanna Briggs Institute (JBI) Scoping Review Methodology Group [Available from:
550 <https://jbi.global/scoping-review-network/resources>].
- 551 9. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
552 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*.
553 2018;169(7):467-73.
- 554 10. National Tuberculosis Association. Transactions of the Annual Meeting. New York:
555 National Tuberculosis Association, 1919 - 1954. Hathi Trust Digital Library.
- 556 11. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. .
- 557 12. Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case finding of tuberculosis:
558 historical perspective and future prospects. *Int J Tuberc Lung Dis*. 2005;9(11):1183-203.
- 559 13. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. *Trends Microbiol*.
560 2009;17(5):183-8.
- 561 14. Chao MC, Rubin EJ. Letting sleeping dogs lie: does dormancy play a role in tuberculosis?
562 *Annu Rev Microbiol*. 2010;64:293-311.
- 563 15. Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early
564 disease states in the context of host immune response. *J Infect Dis*. 2011;204 Suppl 4(Suppl
565 4):S1179-86.
- 566 16. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? *Immunol Res*.
567 2011;50(2-3):202-12.
- 568 17. Kunnath-Velayudhan S, Gennaro ML. Immunodiagnosis of tuberculosis: a dynamic view
569 of biomarker discovery. *Clin Microbiol Rev*. 2011;24(4):792-805.
- 570 18. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in
571 patients living with HIV infection. *Clin Dev Immunol*. 2011;2011.
- 572 19. Sridhar S, Pollock K, Lalvani A. Redefining latent tuberculosis. *Future Microbiol*.
573 2011;6(9):1021-35.
- 574 20. Esmail H, Barry CE, 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to
575 improved diagnostic and novel treatment strategies. *Drug Discov Today*. 2012;17(9-10):514-21.
- 576 21. Ernst JD. The immunological life cycle of tuberculosis. *Nat Rev Immunol*.
577 2012;12(8):581-91.
- 578 22. Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis infection.
579 *Mediterr J Hematol Infect Dis*. 2013;5(1):e2013070.

- 580 23. Dowdy DW, Basu S, Andrews JR. Is passive diagnosis enough? The impact of
581 subclinical disease on diagnostic strategies for tuberculosis. *Am J Respir Crit Care Med.*
582 2013;187(5):543-51.
- 583 24. Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era
584 of biologics. *J Rheumatol Suppl.* 2014;91:11-6.
- 585 25. Esmail H, Barry CE, 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent
586 tuberculosis. *Philos Trans R Soc Lond B Biol Sci.* 2014;369(1645):20130437.
- 587 26. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In
588 search of a new paradigm for protective immunity to TB. *Nat Rev Microbiol.* 2014;12(4):289-99.
- 589 27. Salgame P, Geadas C, Collins L, Jones-Lopez E, Ellner JJ. Latent tuberculosis infection-
590 -Revisiting and revising concepts. *Tuberculosis (Edinb).* 2015;95(4):373-84.
- 591 28. Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma
592 Release Assays. *Microbiol Spectr.* 2016;4(5).
- 593 29. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. *Nat*
594 *Rev Dis Primers.* 2016;2:16076.
- 595 30. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, et al. Correlates
596 of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. *Eur Respir J.*
597 2016;48(6):1751-63.
- 598 31. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. *Nat Rev Immunol.*
599 2017;17(11):691-702.
- 600 32. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient
601 and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.
602 *Clin Microbiol Rev.* 2018;31(4).
- 603 33. Kik SV, Schumacher S, Cirillo DM, Churchyard G, Boehme C, Goletti D, et al. An
604 evaluation framework for new tests that predict progression from tuberculosis infection to clinical
605 disease. *Eur Respir J.* 2018;52(4).
- 606 34. Lin PL, Flynn JL. The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. *J*
607 *Immunol.* 2018;201(9):2541-8.
- 608 35. Sousa J, Saraiva M. Paradigm changing evidence that alter tuberculosis perception and
609 detection: Focus on latency. *Infect Genet Evol.* 2019;72:78-85.
- 610 36. Houben R, Esmail H, Emery JC, Joslyn LR, McQuaid CF, Menzies NA, et al. Spotting
611 the old foe-revisiting the case definition for TB. *Lancet Respir Med.* 2019;7(3):199-201.
- 612 37. Lewinsohn DM, Lewinsohn DA. New Concepts in Tuberculosis Host Defense. *Clin Chest*
613 *Med.* 2019;40(4):703-19.
- 614 38. McHenry ML, Williams SM, Stein CM. Genetics and evolution of tuberculosis
615 pathogenesis: New perspectives and approaches. *Infect Genet Evol.* 2020;81:104204.
- 616 39. Boom WH, Schaible UE, Achkar JM. The knowns and unknowns of latent
617 Mycobacterium tuberculosis infection. *J Clin Invest.* 2021;131(3).
- 618 40. Kendall EA, Shrestha S, Dowdy DW. The Epidemiological Importance of Subclinical
619 Tuberculosis. A Critical Reappraisal. *Am J Respir Crit Care Med.* 2021;203(2):168-74.
- 620 41. Migliori GB, Ong CWM, Petrone L, D'Ambrosio L, Centis R, Goletti D. The definition of
621 tuberculosis infection based on the spectrum of tuberculosis disease. *Breathe (Sheff).*
622 2021;17(3):210079.
- 623 42. Alebouyeh S, Weinrick B, Achkar JM, Garcia MJ, Prados-Rosales R. Feasibility of novel
624 approaches to detect viable Mycobacterium tuberculosis within the spectrum of the tuberculosis
625 disease. *Front Med (Lausanne).* 2022;9:965359.
- 626 43. Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium
627 tuberculosis. *Nat Rev Microbiol.* 2022;20(12):750-66.
- 628 44. Scriba TJ, Dinkele R, Warner DF, Mizrahi V. Challenges in TB research. *J Exp Med.*
629 2022;219(12).

- 630 45. Yoon SH, Goo JM, Yim JJ, Yoshiyama T, Flynn JL. CT and (18)F-FDG PET
631 abnormalities in contacts with recent tuberculosis infections but negative chest X-ray. *Insights*
632 *Imaging*. 2022;13(1):112.
- 633 46. A Treatise on the Diseases of the Chest, and on Mediate Auscultation. *Med Chir Rev*.
634 1829;10(20):420-2.
- 635 47. Rathbun WL. The Classification of Pulmonary Tuberculosis. *American Review of*
636 *Tuberculosis*, 1917;1(1), pp. 1–15.
- 637 48. Brown L. The classification of pulmonary tuberculosis and statistical reports of
638 sanatoriums. *JAMA*. 1909;LII(5):341-8.
- 639 49. Robertson N. Co-ordination of statistics of tuberculosis institutions. *Tubercle*.
640 1920;2(3):97-109.
- 641 50. National Association of the Study and Prevention of Tuberculosis. *Transactions of the*
642 *First Annual Meeting*. 1905.
- 643 51. Long ER, Hopkins FD. History of Diagnostic Standards and Classification of
644 Tuberculosis of the National Tuberculosis Association. *Am Rev Tuberc*. 1952;65(4):494-504.
- 645 52. Standards for the Diagnosis, Classification and Treatment of Tuberculosis in Children
646 and Adults. *American Review of Tuberculosis*, 1917 1(10), pp. 622–631.
- 647 53. Weg JG. Diagnostic standards of tuberculosis--revised. *JAMA*. 1976;235(13):1329-30.
- 648 54. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This
649 official statement of the American Thoracic Society and the Centers for Disease Control and
650 Prevention was adopted by the ATS Board of Directors, July 1999. This statement was
651 endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J*
652 *Respir Crit Care Med*. 2000;161(4 Pt 1):1376-95.

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668